223 related articles for article (PubMed ID: 22742646)
1. Ewing's sarcoma: overcoming the therapeutic plateau.
Subbiah V; Kurzrock R
Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
[TBL] [Abstract][Full Text] [Related]
2. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
Subbiah V; Brown RE; Jiang Y; Buryanek J; Hayes-Jordan A; Kurzrock R; Anderson PM
PLoS One; 2013; 8(7):e68985. PubMed ID: 23922674
[TBL] [Abstract][Full Text] [Related]
3. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
5. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM
Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547
[TBL] [Abstract][Full Text] [Related]
6. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
7. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
[TBL] [Abstract][Full Text] [Related]
9. Ewing's sarcoma: standard and experimental treatment options.
Subbiah V; Anderson P; Lazar AJ; Burdett E; Raymond K; Ludwig JA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):126-40. PubMed ID: 19533369
[TBL] [Abstract][Full Text] [Related]
10. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
[TBL] [Abstract][Full Text] [Related]
11. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
[TBL] [Abstract][Full Text] [Related]
12. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
14. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
15. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
16. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
de Alava E; Kawai A; Healey JH; Fligman I; Meyers PA; Huvos AG; Gerald WL; Jhanwar SC; Argani P; Antonescu CR; Pardo-Mindan FJ; Ginsberg J; Womer R; Lawlor ER; Wunder J; Andrulis I; Sorensen PH; Barr FG; Ladanyi M
J Clin Oncol; 1998 Apr; 16(4):1248-55. PubMed ID: 9552022
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
19. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
